| Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) (NCT07191535) | Foresee Pharmaceuticals Co., Ltd. | 2027-03-01 |
| Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer (NCT06795178) | Foresee Pharmaceuticals Co., Ltd. | 2025-07-01 |
| Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer (NCT06795191) | Foresee Pharmaceuticals Co., Ltd. | 2025-06-01 |
| Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward) (NCT06475781) | Foresee Pharmaceuticals Co., Ltd. | 2025-03-01 |
| Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers (NCT06334211) | Foresee Pharmaceuticals Co., Ltd. | 2024-04-16 |
| A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia (NCT04522375) | Foresee Pharmaceuticals Co., Ltd. | 2023-06-30 |
| Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty (NCT05493709) | Foresee Pharmaceuticals Co., Ltd. | 2023-06-02 |
| A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19 (NCT04750278) | Foresee Pharmaceuticals Co., Ltd. | 2021-04-06 |
| Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer (NCT03261999) | Foresee Pharmaceuticals Co., Ltd. | 2017-09-26 |